All In Biotech

Drug Trial Radar · NCT02478840

Evaluation of Long-term Efficacy of Treatment With Lamazym

A Single Center, Open Label Clinical Trial Investigating the Long-term Efficacy of rhLAMAN (Recombinant Human Alpha-mannosidase or Lamazym) Treatment in Subjects With Alpha-Mannosidosis Who Previously Participated in Lamazym Trials

Last checked: Nov 20, 2026Latest source record: Nov 20, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

18

Actual

Start

Feb 2015

Primary completion

Jun 2015

Study completion Jun 2015

Sponsor

Lead sponsor
Zymenex A/SIndustry
Sponsor type
Industry
First posted
Jun 23, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overall objective is to evaluate the long-term efficacy of Lamazym i.v. treatment in patients with alpha-Mannosidosis previously enrolled in Lamazym trials and currently receiving the treatment according to the AfterCare Program.

Conditions

  • Alpha-Mannosidosis

Interventions

  • LamazymDrug

    recombinant human alpha-mannosidase

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in reduction of oligosaccharides in serumTime frame: Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment
  2. Change from baseline in 3 Minutes Stair Climb Test (3MSCT)Time frame: Baseline evaluation prior to first dose compared to evaluation after one, two or four years of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Center for Metabolic Diseases, Department of Clinical Genetics, Juliane Marie Centre, Copenhagen University Hospital, Blegdamsvej 9

    Copenhagen, Denmark

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.